Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management

Activity Overview

Antibody-drug conjugates (ADCs) are reshaping the treatment of solid tumors, pairing target-directed antibodies with potent cytotoxic payloads to deliver therapy more selectively than conventional chemotherapy. As highly actionable targets, human epidermal growth factor receptor 2 (HER2), trophoblast cell-surface antigen 2 (TROP2), and folate receptor alpha (FRα) anchor a growing set of FDA-approved ADCs, while emerging agents directed at B7 homolog 3 protein (B7-H3) and cadherin-6 (CDH6) extend the class across breast, lung, gynecologic, and other cancers. These advances bring new options for patients, but also introduce distinct, agent-specific toxicities, including interstitial lung disease, ocular toxicity, stomatitis, and myelosuppression, that demand specialized nursing expertise.

This CME-certified Show Me Your Care Plan!™ symposium convenes a multidisciplinary panel of oncology experts to translate evolving ADC science into practical, nursing-centered strategies for real-world care. In this format, physician faculty set the treatment strategy and nursing faculty build the care plan. Through concise didactic updates and case-based discussions, the faculty will deliver actionable insights on therapeutic targets and payloads, adverse event recognition and management, biomarker-informed decision-making, and patient counseling. This dynamic program equips oncology nurses to confidently and safely implement ADC therapies across diverse practice settings.

This educational activity is an archive of the live virtual symposium held on August 24, 2026.

Target Audience

This educational activity is directed toward oncology nurses and other health care providers who manage patients with solid tumors.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Identify key therapeutic targets for approved and emerging ADCs across various solid tumors
• Evaluate recent clinical trial data on ADC therapies and their impact on patient outcomes and nursing responsibilities
• Implement evidence-based monitoring and management protocols to recognize, assess, and address adverse events specific to ADC treatments
• Apply patient counseling techniques to clearly explain ADC mechanisms, biomarker-based treatment decisions, side-effect management, and quality-of-life concerns

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.

This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.

The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.

This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.